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Summary 
Tumor development is a Darwinian evolutionary process, involving the interplay between 
cancer subclones and the local immune microenvironment. These complex interactions are 
highlighted in this issue of Cell by the results from a deep analysis of one patient with 
advanced serous carcinoma of the ovary (Jiménez-Sánchez et al., 2017).  
 
Main Text 
Recent years have seen a rejuvenation in the field of cancer evolution, with an increasing 
number of clinical studies revealing the impact of genetic heterogeneity, the substrate for 
cancer evolution, on the acquisition of drug resistance, biomarker qualification and clinical 
outcome (Greaves, 2015).  
 
Coincident with a renewed interest in the field of cancer evolution, and appreciation of the 
limitations of targeting single genomic alterations, cancer immunotherapy has risen like a 
phoenix from the flames as the new hope in cancer medicine. An impressive array of 
antibodies, effectively releasing the breaks from the immune system, have entered clinical 
practice with a range of FDA approvals across distinct tumor types over the last 18 months, 
in many cases offering meaningful overall survival benefits (Topalian et al., 2012).  
 
The (re-)emergence of the fields of both cancer evolution and immunotherapy has led to an 
appreciation that tumor development is not determined solely by genetic alterations in tumor 
cells, but also by the fitness advantage such mutations confer within a given environment 
and geographic location (Junttila and de Sauvage, 2013). As such, just as knowledge of 
ecological niches and geographical barriers are required to understand species evolution, an 
understanding of immune surveillance and the constraints the local immune environment 
imposes upon an evolving tumor entity are central to deepen knowledge about a cancer’s 
origin and its fate (Figure 1).  
 
With this in mind, in this issue of Cell, Snyder and Miller and colleagues (Jiménez-Sánchez 
et al., 2017) perform a deep analysis of one patient with advanced serous carcinoma of the 
ovary to understand the interactions of an evolving tumor at multiple distinct sites of disease 
within the constraints of the local tumor microenvironment. The authors focus on an often-
overlooked phenomenon in cancer management, namely the occurrence of heterogeneous 
responses across geographically distinct tumor lesions, with simultaneous regression and 
progression of tumor metastases at distinct anatomical locations.   
 
The patient underwent surgical debulking, followed by platinum combination therapy, and 
experienced disease recurrence within 7 months, followed by multiple lines of cytotoxic 
therapies over the course of the next 3 years. Following exhaustion of all standard lines of 
therapy, the patient was offered best supportive care and on follow-up off chemotherapy her 
CA125 tumor marker began to fall with differential growth of her metastatic lesions with a 
new growth in the vaginal cuff. Owing to her long treatment free interval (a marker of 
prognosis in this disease which guides management), she underwent a further debulking 
procedure which revealed widespread metastatic disease involving the liver capsule, splenic 
hilum, right upper quadrant of the abdomen and recto-vaginal space.  
 
The authors subjected the tissue from the resected specimens to a range of immune-
genomic analyses including exome sequencing, RNA expression data, neo-epitope 
prediction, immunohistochemistry, and in-situ T cell receptor sequencing for tumor infiltrating 
immune cells.  
 
The sites of metastases (vaginal cuff and liver), which had developed later in the disease-
course, after extensive treatment, had the highest tumor mutation and neo-epitope loads, 
however, no predicted neo-epitopes were found to be shared between regressing and 
progressing tumors. The differential growth rates at the different metastatic sites was 
reflected in the propensity for mutations to yield neo-epitopes at different sites, with evidence 
of immune editing in the regressing right upper quadrant lesion compared to the progressing 
vaginal cuff and splenic lesions. Immune activation scores (immunophenoscores) and T-cell 
infiltrate was also higher in regressing lesions than stable or progressing ones. The 
implications are that while the immune system can successfully prune some tumor 
branches, others may advance unrestrained from immune micro-environmental predation, 
consistent with the possibility that genetic heterogeneity might permit immune escape.  
 
Lower immunogenicity scores were found for clonal/truncal somatic mutations than in 
branched, subclonal, mutations and the primary tumor demonstrated no quantifiable T cell 
infiltration, as well as negativity for PD-L1 and CD-68. These data mirror recent evidence 
that clonal neo-epitopes present in every tumor cell are the most potent mediators of 
immune-predation, and therefore subject to the highest selection pressures to be eliminated 
(McGranahan et al., 2016). If this is a general phenomenon, this may act as a barrier to the 
success of immunotherapies in ovarian cancers.  
The case study provides evidence of divergent tumor genetics, tumor microenvironments, 
and immune activation within a single patient and supports a growing body of work 
suggesting that a single biopsy is insufficient to fully characterize a tumor, its 
microenvironment and understand its development.  The findings, assuming they translate 
more broadly across patients with this disease, raise several important questions and 
challenges.  
 
Firstly, the heterogeneity observed in both response and immune infiltration across different 
sites raises important clinical challenges for the use of cytotoxic-, targeted-, and 
immunotherapies. The work emphasizes the pressing need to distinguish stable immune 
parameters from dynamic ones, both in terms of designing optimal immune-based 
combinations as well as to drive effective companion biomarker development (Topalian et 
al., 2016). An appreciation of the heterogeneity of immune parameters between different 
metastatic sites, including spatial distribution of T cells within and around a tumor and 
checkpoint molecule expression such as PDL1, will be important in the development of new 
biomarkers, predictive of response to immune based therapies. Such studies highlight the 
critical role of extensive tumor sampling of metastatic disease, linked with imaging analyses, 
to understand this diverse landscape in relation to tumor response. An essential model to 
study such complexity will be through autopsy analyses of patients with end-stage cancers, 
in programs such as PEACE in the United Kingdom.  
 
Secondly, the findings presented by Miller and colleagues emphasize the importance of 
developing a deeper understanding of the impact of treatment on tumor evolution and 
immune predation. The divergent growth rates at different tumor sites speaks to the need to 
understand how therapy itself can contribute to heterogeneous responses. The repeated 
rounds of platinum chemotherapy may directly sculpt the cancer genome by inducing 
heterogeneous mutations, which may be immunogenic, and it may also act as a selection 
barrier, altering the evolutionary trajectory and selecting for growth of specific subclones 
within specific immune environments.  
Finally, the results also highlight the need to further explore molecular mechanisms 
underpinning immune evasion and its relationship with the genomic landscape and extent of 
heterogeneity. Can branched tumor evolution and diversity within tumors be traced back to a 
failure of immune predation or do cancer mutational processes, which foster cell-to-cell 
variation, actively provide a means of immune evasion?  
 
Aristotle, Darwin and Wallace, among others, recognized the importance of the analysis of 
geographically isolated island populations to developing insights into nature’s rulebook and 
speciation (Stott, 2012). This case study emphasizes the importance of an integrative 
approach to understanding the molecular mechanisms governing evolution of geographically 
distinct cell populations manifested as the interaction between the tumor and its immune 
microenvironment. A deeper understanding of this interplay will be required to harness an 
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Figure 1 Analysis of geographically isolated populations sheds light on evolution. 
A) Darwin’s formulation of the theory of evolution by natural selection was influenced by his 
discovery of several distinct species of finches, adapted to specific ecological niches on 
different Galapagos islands. The top panel shows the phylogenetic relationship between 
different finch species, and the bottom panel depicts the different islands where these 
species are found. For simplicity, only finch species found on only one island are depicted. 
B) The analysis of geographically distinct tumor sites and their microenvironmental 
constraints can aid our understanding of tumor evolution. The bottom panel shows the 
different tumor sites and the top panel depicts the phylogenetic relationship between cancer 
cells found at each site. Just as each Galapagos island exhibits specific ecological niches, 
geographically distinct tumor sites likely exhibit specific immune microenvironments.  
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